Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc (RPRX) is the subject of an amended ownership report in which FMR LLC and Abigail P. Johnson each report beneficial ownership of 19,288,880.43 Class A common shares, or 4.3% of the class.
FMR LLC reports sole voting power over 14,091,863.23 shares and sole dispositive power over 19,288,880.43 shares; Abigail P. Johnson reports 0.00 sole voting power and sole dispositive power over 19,288,880.43 shares. Both report 0.00 shared voting and dispositive power.
Royalty Pharma plc (RPRX) reported third-quarter 2026 total income and other revenues of $690.1 million, compared with $609.3 million a year earlier. Net income attributable to Royalty Pharma was $144.7 million, down from $284.2 million; consolidated net income was $266.6 million versus $440.2 million. For the first nine months, operating cash flow was $2,132.8 million, compared with $1,662.7 million.
The quarter included a $150.4 million noncash impairment related to the pelacarsen royalty asset after Novartis announced that its Phase 3 trial did not meet the primary endpoint; impairment charges for the first nine months totaled $219.8 million. During those nine months, Royalty Pharma repurchased 3.5 million Class A ordinary shares for approximately $182.8 million. Approximately $1.6 billion remained under its $3.0 billion repurchase program as of September 30, 2026. Cash and cash equivalents were $513.7 million at quarter-end.
Royalty Pharma plc (RPRX) reported third-quarter 2026 Portfolio Receipts of $890 million, up 9% year over year, including Royalty Receipts of $883 million, also up 9%. Net cash provided by operating activities was $686 million, compared with $703 million a year earlier. Adjusted EBITDA, a non-GAAP liquidity measure, was $840 million, up 8%, and Portfolio Cash Flow was $673 million, up 2%.
The company raised full-year 2026 Portfolio Receipts guidance to $3,500 million to $3,550 million from $3,400 million to $3,500 million, excluding contributions from future transactions; expected Royalty Receipts growth is 10% to 11%. As of September 30, 2026, cash and cash equivalents were $514 million and total debt with principal value was $8.8 billion. A $380 million term-loan payment in July reduced total debt from $9.2 billion as of June 30, 2026.
Net income attributable to Royalty Pharma was $145 million, compared with $284 million a year earlier. The Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint; Royalty Pharma recorded a $150 million non-cash impairment charge related to pelacarsen. It acquired a Zoryve royalty for $100 million upfront and a Mimrylo royalty for $100 million, including $50 million upfront and $50 million payable on the first anniversary of closing.
Royalty Pharma plc’s EVP, Research & Investments, Marshall Urist, sold 4,126 Class A Ordinary Shares on October 5, 2026, at $57.10 per share under a Rule 10b5-1 plan adopted June 26, 2026. The reported direct holding following the sale was 0 shares; a separate line lists 19,020 shares held indirectly by IRA.
Royalty Pharma plc officer Marshall Urist reported a proposed sale of 4,126 shares, with an aggregate market value of $235,594.60, through Merrill Lynch; the approximate sale date is October 5, 2026. The shares are identified as Class A ordinary shares from an equity performance award granted August 7, 2026. Urist also reported sales of 9,099 shares on July 1, 2026, for $508,453.82, and 4,126 shares on September 28, 2026, for $238,812.88.
Royalty Pharma plc (RPRX) director Bonnie L. Bassler acquired 642 Class A Ordinary Shares on September 30, 2026, under the 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Her direct holdings following the award were 79,823 shares.
Royalty Pharma plc (RPRX) EVP, Research & Investments Marshall Urist sold 4,126 Class A Ordinary Shares on September 28, 2026, at $57.88 per share under a Rule 10b5-1 plan adopted June 26, 2026. After the sale, he reported 4,126 shares held directly and 19,020 shares held indirectly through an IRA.
Separately, Urist and family vehicles controlled by him reported limited partnership interests exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd. exchangeable into 1,356,528 Class A Ordinary Shares. The Class E Ordinary Shares are subject to vesting conditions.
Royalty Pharma plc (RPRX) lists Officer Marshall Urist's proposed sale of 4,126 Class A ordinary shares, with an aggregate market value of $238,812.88 and Merrill Lynch named as broker. The shares are identified as an equity performance award granted by Royalty Pharma on August 5, 2026; the notice lists September 28, 2026, as the sale date. Shares outstanding were 445,277,344 as of September 28, 2026.
At Royalty Pharma plc, EVP & Chairman, Partnering Christopher Hite reported that SCH Investment Partners LLC sold 100,000 Class A ordinary shares on September 22, 2026: 96,073 at a weighted average $58.5148 per share and 3,927 at $58.9261. The sales were made under a Rule 10b5-1 plan adopted March 20, 2026. Hite held 23,200 shares directly after the transactions; family vehicles also hold interests exchangeable into 866,410 Class A ordinary shares and Class E shares exchangeable into 1,238,789 Class A ordinary shares, with vesting conditions applying to the Class E shares.
Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares under Rule 144 through Merrill Lynch. The proposed sale has an approximate aggregate market value of $5,846,972.43, compared with 445,277,344 Class A Ordinary Shares outstanding. SCH Investment Partners LLC previously sold 350,000 Class A Ordinary Shares during the past three months under a Rule 10b5-1(c) selling plan dated March 20, 2026.